The Drug Controller Basic of India at present gave the go-ahead for the Section-III trials
New Delhi:
Vaccine producer Bharat Biotech has obtained approval to conduct Section-III medical trials of an intranasal booster dose on individuals who have obtained each doses of Covaxin.
The Drug Controller Basic of India at present gave the go-ahead for the Section-III trials. The trials might be carried out at 9 places within the nation.
An intranasal vaccine as a booster might be simpler to manage in mass vaccination drives.
Discover more from News Journals
Subscribe to get the latest posts sent to your email.
